The Phosphoinositide 3 Kinase (PI3K) market is a subset of the oncology drug market. PI3K inhibitors are a type of targeted therapy used to treat cancer. They work by blocking the activity of the PI3K enzyme, which is involved in the growth and spread of cancer cells. PI3K inhibitors are used to treat a variety of cancers, including breast, ovarian, and lung cancer. They are also used in combination with other treatments, such as chemotherapy and radiation therapy. PI3K inhibitors are a relatively new type of cancer treatment, and the market is still in its early stages. However, the potential of PI3K inhibitors to improve outcomes for cancer patients has led to increased investment in the development of new drugs. Several companies are currently developing PI3K inhibitors, including AstraZeneca, Novartis, and Pfizer. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
